Merck & Co., Inc.'s Q4 earnings call highlighted several positive developments, including six new product approvals in 2014, a robust pipeline advancement, and strategic acquisitions like Cubist. These indicators suggest a strong growth trajectory, especially with products like KEYTRYUDA impacting Oncology with potential approvals in lung cancer on the horizon, and a promising Hep C therapy in development. However, managementâ€™s guidance includes a significant negative impact from currency fluctuations and a competitive environment in the Hep C market, which may temper immediate market reactions. The company's focus on innovation and their active pursuit of external collaborations are positive for the medium-term runway. 
[1]